When vagal maneuvers fail to terminate stable narrow-complex SVT, the primary medication of choice is adenosine. For the unstable patient with a regular and narrow QRS complex, adenosine may also be considered prior to synchronized cardioversion.
Adenosine is the primary drug used in the treatment of stable narrow-complex SVT (Supraventricular Tachycardia). Now, adenosine can also be used for regular monomorphic wide-complex tachycardia.
When given as a rapid IV bolus, adenosine slows cardiac conduction particularly affecting conduction through the AV node. The rapid bolus of adenosine also interrupts reentry (SVT causing) pathways through the AV node and restores sinus rhythm in patients with SVT.
When injected into the body, adenosine is rapidly absorbed by red blood cells and blood vessel endothelial cells and metabolized for natural uses throughout the body. In light of this adenosine should be administered by RAPID intravenous bolus so that a significant bolus of adenosine reaches the heart before it is metabolized.
A change from the 2010 guidelines now has adenosine given up to two times rather than three.
Dosing
The first dose of adenosine should be 6 mg administered rapidly over 1-3 seconds followed by a 20 ml NS bolus. If the patient’s rhythm does not convert out of SVT within 1 to 2 minutes, a second 12 mg dose may be given in a similar fashion. All efforts should be made to administer adenosine as quickly as possible.
A lower initial dose of 3mg should be used for patients taking dipyridamole or carbamazepine as these two medications potentiate the effects of adenosine.
Also, prolonged asystole has been seen with the use of normal doses of adenosine in heart transplant patients and central line use. Therefore, the lower dose (3mg) may be considered for patients with a central venous line or a history of heart transplant.
Precautions
Some side effects of adenosine administration include flushing, chest pain/tightness, brief asystole or bradycardia.
Make sure that adenosine is not used for irregular, polymorphic wide-complex tachycardia and unstable VT. Use in these cases may cause clinical deterioration.
Return to ACLS Drugs Main Page.
Kelli Anderson says
June 7, 2019 at 9:15 amSome sources indicate the dosing of Adenosine is cut in half if the patient has a central line. Why is this not included in guidelines?
ACLS says
June 9, 2019 at 9:42 pmThis is mentioned in the Guidelines here: AHA Guidelines Ref for Adenosine Central Line Use
Kind regards, Jeff
RHONDA STAFFORD says
May 21, 2019 at 10:15 amIS IT EVER ACCEPTABLE TO GIVE ADENOSINE 18 MG….I WOULD BE REFUSING TO GIVE R/T ACLS GUIDELINES TO NOT COVER US….
Jeff with admin. says
May 24, 2019 at 12:36 pmIt is not recommended or discussed within the AHA guidelines, but It may be acceptable in certain situations. Here are a couple of links to research articles regarding the topic.
Adenosine Article 1
Adenosine Article 2
Kind regards, Jeff
Suja says
April 16, 2019 at 7:43 amWhat’s the reason for giving the second dose of adenosine after 2 minutes why not immediately
Jeff with admin. says
April 18, 2019 at 2:50 amI do not know the reason for delaying the second dose of adenosine for two minutes. I could not find a explanation for this anywhere. The half-life of adenosine is less than 10 seconds and so the adenosine would be completely metabolized within a maximum time of 30 seconds.
It would seem logical that a second dose could be given after 30-60 seconds, but the guidelines clearly state that it may be repeated after 1-2 minutes.
Here is the reference from the AHA website: AHA Adenosine
Kind regards,
Jeff
Martin says
January 29, 2019 at 9:05 amI have been told that you can give adenosine three times! 6 mg, 12 mg, and 12mg. Is this true?
Jeff with admin. says
January 30, 2019 at 12:39 pmPrior to 2010, the American heart Association guidelines called for the administration of 6 mg, 12 mg, and 12mg.
After 2010, the 3 dose schedule was dropped for the two doses of 6mg and 12mg.
I was never able to determine the exact reason for this change, however my assumption was that the third dose of 12 mg was not typically needed and SVT conversion what are usually accomplished with the two initial doses.
Many providers still include the third dose of 12 mg on the schedule and this is fine. It’s just not included in the American heart Association guidelines any longer.
Kind regards,
Jeff